Metraipolis › archive › dc_15e75a313da1

Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study — Europe PMC PMID:41078351

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41078351
DOI
10.2340/1651-226x.2025.43794
License (as archived)
solo-consultazione
Archived
2026-11-09T08:44:26.507Z
SHA-256 of the archived text
338010aa20ff08834687fd0f2d6af4e36e45a8b9b02fb38494175e0af7b92d21
Stable URL of this page
https://metraipolis.com/documento/dc_15e75a313da1

How to cite

Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study — Europe PMC PMID:41078351 — Europe PMC (en), https://europepmc.org/article/MED/41078351 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_15e75a313da1 (Metraipolis archive dc_15e75a313da1, sha256 338010aa20ff08834687fd0f2d6af4e36e45a8b9b02fb38494175e0af7b92d21)
BibTeX
@misc{dc15e75a313da1,
  title = {Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study — Europe PMC PMID:41078351},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41078351},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_15e75a313da1; sha256 338010aa20ff08834687fd0f2d6af4e36e45a8b9b02fb38494175e0af7b92d21},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41078351. Agents can read the archived copy with the MCP tool read_document.